Strategic Growth Nova Biomedical's consolidation from Advanced Instruments creates a larger global life science tools platform with expanded capabilities in bioprocessing and clinical diagnostics, suggesting cross-sell opportunities across existing customer bases in bioprocessing, cell culture monitoring, and IVD workflows.

Integrated Portfolio A combined portfolio spanning clinical diagnostics, bioprocessing solutions, and veterinary diagnostics enables bundled offerings and integrated solutions that can address end-to-end lab workflows, inviting sales pitches around turnkey systems and maintenance contracts.

Global Reach With customers in more than 100 countries and the largest privately held IVD position in the U.S., there is substantial potential to expand enterprise deals, regional deployments, and service agreements in underserved markets.

Innovation Pipeline Ongoing reinvestment in R&D and a strong breakthrough pipeline provide opportunities to upsell early access programs, pilot projects, and technology refresh cycles to customers seeking the latest high-performance analytics and cell culture monitoring tools.

Security and Reliability Past cybersecurity incident highlights a need for robust cybersecurity solutions and validated compliance offerings; positioning security-enhanced analytics platforms and hardware-software integration services can be a differentiator for risk-averse clinical and bioprocess customers.